

## National Latino AIDS Awareness Day — October 15, 2012

National Latino AIDS Awareness Day is observed each year to increase awareness of the disproportionate impact of human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) on the Hispanic or Latino population in the United States. In 2009, the estimated percentage of persons in the United States with HIV infection who did not know they were infected was 19.7% among Hispanics or Latinos, compared with 14.8% among non-Hispanic whites (1). National Latino AIDS Awareness Day, October 15, 2012, is an opportunity to encourage increased HIV prevention activities, such as HIV testing and linkage to care and treatment, for Hispanics or Latinos.

Two of the goals of the National HIV/AIDS Strategy are to reduce HIV incidence and to reduce HIV-related disparities (2). For 2009, estimates of HIV incidence indicated that Hispanics or Latinos had a rate of 26.4 per 100,000 population, compared with 9.1 for non-Hispanic whites (3).

CDC supports testing, access to care and treatment, and a range of other efforts to reduce HIV infection among Hispanics or Latinos. Additional information about CDC activities for National Latino AIDS Awareness Day and HIV resources is available at <http://www.cdc.gov/hiv/latinos/index.htm>.

### References

1. CDC. Monitoring selected national HIV prevention and care objectives using HIV surveillance data—United States and 6 U.S. dependent areas—2010. HIV surveillance supplemental report 2012;17(No. 3, part A). Available at [http://www.cdc.gov/hiv/surveillance/resources/reports/2010supp\\_vol17no3/index.htm](http://www.cdc.gov/hiv/surveillance/resources/reports/2010supp_vol17no3/index.htm). Accessed October 4, 2012.
2. Office of National AIDS Policy. The National HIV/AIDS strategy for the United States and the National HIV/AIDS strategy: federal implementation plan. Washington, DC: Office of National AIDS Policy; 2010. Available at <http://www.whitehouse.gov/onap/nhas>. Accessed October 10, 2012.
3. Prejean J, Song R, Hernandez A, et al. Estimated HIV incidence in the United States, 2006–2009. PLoS ONE 2011;6:e17502.

## Geographic Differences in HIV Infection Among Hispanics or Latinos — 46 States and Puerto Rico, 2010

In the United States, Hispanics or Latinos are disproportionately affected by infection with human immunodeficiency virus (HIV). In 2010, new diagnoses of HIV infection among Hispanics or Latinos occurred at an annual rate that was 2.8 times that of non-Hispanic whites (20.4 versus 7.3 per 100,000 persons) (1). To further assess HIV infection among Hispanics or Latinos in the United States, CDC analyzed the geographic distribution of new diagnoses in 2010 in 46 states and Puerto Rico and the characteristics of those diagnosed. The results of this analysis determined that a lower percentage of infections were attributed to male-to-male sexual contact in Puerto Rico than in the 46 states (36.1% versus 66.5%) and a higher percentage were attributed to heterosexual contact (40.7% versus 22.0%) or injection-drug use (IDU) (20.4% versus 8.6%). In the 46 states, the rate of new diagnoses of HIV infection among Hispanics or Latinos in the Northeast Census region in 2010 (55.0 per 100,000 persons) was more

### INSIDE

- 811 Evaluation of Vaccination Recall Letter System for Medicaid-Enrolled Children Aged 19–23 Months — Montana, 2011
- 816 Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
- 820 Severe Respiratory Illness Associated with a Novel Coronavirus — Saudi Arabia and Qatar, 2012
- 821 Announcements
- 822 QuickStats

Continuing Education examination available at [http://www.cdc.gov/mmwr/cme/conted\\_info.html#weekly](http://www.cdc.gov/mmwr/cme/conted_info.html#weekly).



than twice as high as in other regions, and a higher percentage of those with a new HIV diagnosis were born in Puerto Rico or had their HIV infection attributed to IDU, compared with other regions. Geographic differences in HIV infection among Hispanics or Latinos should be addressed with HIV testing, prevention, and treatment efforts tailored to specific communities.

Data were analyzed for Hispanics or Latinos\* with newly diagnosed HIV infection in 2010 who were aged  $\geq 13$  years at HIV diagnosis and for those living with a diagnosis of HIV infection who were aged  $\geq 13$  years at the end of 2009. The data were reported to CDC through June 2011 by Puerto Rico, which represented 98.1% of Hispanics or Latinos diagnosed with HIV infection in five U.S. dependent areas† in 2010, and the 46 states. All of these reporting areas have had confidential, name-based HIV infection reporting since at least January 2007. The numbers and percentages of HIV diagnoses in 2010 among Hispanic or Latino adolescents and adults in each U.S. Census region§ and Puerto Rico were calculated by sex, age group, transmission category, residence at diagnosis, and place of birth. The

\* Hispanics or Latinos might be of any race.

† The five U.S. dependent areas are American Samoa, Guam, the Northern Mariana Islands, Puerto Rico, and the U.S. Virgin Islands.

§ *Northeast*: Connecticut, Maine, New Hampshire, New Jersey, New York, Pennsylvania, and Rhode Island; *Midwest*: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin; *South*: Alabama, Arkansas, Delaware, Florida, Georgia, Kentucky, Louisiana, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, and West Virginia; *West*: Alaska, Arizona, California, Colorado, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming.

number of diagnoses of HIV infection was adjusted for reporting delay but not for incomplete reporting. Multiple imputation was used to assign a transmission category to those cases missing risk information (2,3). The number of persons living with a diagnosis of HIV infection (prevalence of diagnosed HIV infection) was further adjusted to account for the delay in reporting of deaths among persons with HIV. Where possible, rates per 100,000 persons were calculated based on postcensal estimates of Hispanic populations from the U.S. Census Bureau (4).

## New Diagnoses of HIV Infection

In 2010, an estimated total of 10,731 Hispanics or Latinos were newly diagnosed with HIV infection in 46 states (9,620 [89.6%]) and Puerto Rico (1,111 [10.4%]) (Table 1). By category, 83.2% were males, 63.4% were men who had sex with men, and 86.4% were urban residents; infection was most common (32.4%) among persons aged 25–34 years. Among the 8,966 (83.6%) cases with birthplace data available, 54.4% of new diagnoses were in persons born outside of the 50 states and the District of Columbia; the highest percentages were from Mexico (19.4%) and Puerto Rico (15.8%). Compared with new diagnoses of HIV infection among Hispanics or Latinos in the 46 states, lower percentages of diagnoses in Hispanics or Latinos in Puerto Rico were among males (75.3% versus 84.1%), men who had sex with men (36.1% versus 66.5%), and urban residents¶ (69.8% versus 88.3%); higher percentages were among

¶ Residents of metropolitan areas with  $\geq 500,000$  population.

The *MMWR* series of publications is published by the Office of Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30333.

**Suggested citation:** Centers for Disease Control and Prevention. [Article title]. *MMWR* 2012;61:[inclusive page numbers].

### Centers for Disease Control and Prevention

Thomas R. Frieden, MD, MPH, *Director*

Harold W. Jaffe, MD, MA, *Associate Director for Science*

James W. Stephens, PhD, *Director, Office of Science Quality*

Stephen B. Thacker, MD, MSc, *Deputy Director for Surveillance, Epidemiology, and Laboratory Services*

Stephanie Zaza, MD, MPH, *Director, Epidemiology and Analysis Program Office*

### MMWR Editorial and Production Staff

Ronald L. Moolenaar, MD, MPH, *Editor, MMWR Series*

John S. Moran, MD, MPH, *Deputy Editor, MMWR Series*

Teresa F. Rutledge, *Managing Editor, MMWR Series*

Douglas W. Weatherwax, *Lead Technical Writer-Editor*

Donald G. Meadows, MA, Jude C. Rutledge, *Writer-Editors*

Martha F. Boyd, *Lead Visual Information Specialist*

Maureen A. Leahy, Julia C. Martinroe,

Stephen R. Spriggs, Terraye M. Starr

*Visual Information Specialists*

Quang M. Doan, MBA, Phyllis H. King

*Information Technology Specialists*

### MMWR Editorial Board

William L. Roper, MD, MPH, Chapel Hill, NC, *Chairman*

Matthew L. Boulton, MD, MPH, Ann Arbor, MI

Virginia A. Caine, MD, Indianapolis, IN

Jonathan E. Fielding, MD, MPH, MBA, Los Angeles, CA

David W. Fleming, MD, Seattle, WA

William E. Halperin, MD, DrPH, MPH, Newark, NJ

King K. Holmes, MD, PhD, Seattle, WA

Deborah Holtzman, PhD, Atlanta, GA

Timothy F. Jones, MD, Nashville, TN

Dennis G. Maki, MD, Madison, WI

Patricia Quinlisk, MD, MPH, Des Moines, IA

Patrick L. Remington, MD, MPH, Madison, WI

John V. Rullan, MD, MPH, San Juan, PR

William Schaffner, MD, Nashville, TN

Dixie E. Snider, MD, MPH, Atlanta, GA

John W. Ward, MD, Atlanta, GA

**TABLE 1. Estimated number\* and percentage of new diagnoses of HIV infection among Hispanics or Latinos† aged ≥13 years, by U.S. Census region‡ and selected characteristics — 46 states and Puerto Rico, 2010**

Characteristic	Northeast		Midwest		South		West		Subtotal		Puerto Rico		Total	
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
<b>Sex</b>														
Male	1,943	76.7	501	84.2	2,858	84.0	2,785	90.2	8,087	84.1	837	75.3	8,924	83.2
Female	591	23.3	95	16.0	546	16.0	302	9.8	1,534	15.9	274	24.7	1,807	16.8
<b>Age group at diagnosis (yrs)</b>														
13–24	457	18.0	118	19.8	628	18.4	576	18.7	1,779	18.5	136	12.2	1,916	17.9
25–34	748	29.5	219	36.8	1,104	32.4	1,113	36.1	3,184	33.1	298	26.8	3,482	32.4
35–44	680	26.8	165	27.7	904	26.6	798	25.9	2,547	26.5	283	25.5	2,831	26.4
45–54	422	16.7	62	10.4	555	16.3	429	13.9	1,468	15.3	250	22.5	1,718	16.0
≥55	226	8.9	31	5.2	213	6.3	170	5.5	640	6.7	144	13.0	785	7.3
<b>Transmission category</b>														
<i>Males</i>														
Male-to-male sexual contact	1,331	52.5	397	66.7	2,297	67.5	2,374	76.9	6,399	66.5	401	36.1	6,800	63.4
Injection-drug use	305	12.0	39	6.6	144	4.2	144	4.7	632	6.6	200	18.0	833	7.8
Male-to-male sexual contact and injection-drug use	55	2.2	16	2.7	82	2.4	126	4.1	279	2.9	31	2.8	310	2.9
Heterosexual contact¶	251	9.9	48	8.1	333	9.8	139	4.5	771	8.0	205	18.5	975	9.1
Other**	1	0.0	1	0.2	2	0.1	2	0.1	6	0.1	—	—	5	0.0
<i>Females</i>														
Injection-drug use	96	3.8	13	2.2	50	1.5	32	1.0	191	2.0	27	2.4	217	2.0
Heterosexual contact¶	495	19.5	82	13.8	496	14.6	270	8.7	1,343	14.0	247	22.2	1,588	14.8
Other**	1	0.0	0	0.0	1	0.0	1	0.0	3	0.0	—	—	2	0.0
<b>Residence area at diagnosis</b>														
Urban††	2,362	93.2	473	79.5	2,831	83.2	2,829	91.6	8,495	88.3	775	69.8	9,270	86.4
Suburban§§	115	4.5	60	10.1	340	10.0	204	6.6	719	7.5	233	21.0	952	8.9
Rural¶¶	33	1.3	33	5.5	205	6.0	46	1.5	317	3.3	29	2.6	346	3.2
Unknown	25	1.0	29	4.9	28	0.8	8	0.3	90	0.9	74	6.7	164	1.5
<b>Place of birth</b>														
50 states and DC	1,178	55.7	178	44.1	1,407	50.5	1,296	50.3	4,059	51.5	32	2.9	4,090	45.6
Central America	140	6.6	41	10.1	295	10.6	230	8.9	706	9.0	3	0.3	709	7.9
Cuba	28	1.3	2	0.5	200	7.2	17	0.7	247	3.1	—	—	247	2.8
Mexico	153	7.2	136	33.7	517	18.6	932	36.2	1,738	22.1	2	0.2	1,740	19.4
Puerto Rico	224	10.6	21	5.2	145	5.2	16	0.6	406	5.2	1,009	90.8	1,416	15.8
South America	163	7.7	17	4.2	157	5.6	52	2.0	389	4.9	6	0.5	395	4.4
Other	229	10.8	9	2.2	65	2.3	33	1.3	336	4.3	34	3.1	369	4.1
<b>Overall***</b>	<b>2,534</b>	<b>100.0</b>	<b>595</b>	<b>100.0</b>	<b>3,404</b>	<b>100.0</b>	<b>3,087</b>	<b>100.0</b>	<b>9,620</b>	<b>100.0</b>	<b>1,111</b>	<b>100.0</b>	<b>10,731</b>	<b>100.0</b>

\* Estimates resulted from statistical adjustment that accounted for reporting delays and missing risk-factor information, but not for incomplete reporting.

† Hispanics or Latinos might be of any race.

§ Northeast: Connecticut, Maine, New Hampshire, New Jersey, New York, Pennsylvania, and Rhode Island; Midwest: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin; South: Alabama, Arkansas, Delaware, Florida, Georgia, Kentucky, Louisiana, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, and West Virginia; West: Alaska, Arizona, California, Colorado, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming.

¶ Heterosexual contact with a person known to have, or to be at high risk for HIV infection.

\*\* Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.

†† Metropolitan area of ≥500,000 population.

§§ Metropolitan area of 50,000–499,999 population.

¶¶ Nonmetropolitan area of <50,000 population.

\*\*\* Because column totals for estimated numbers were calculated independently of the values for the subpopulations, the values in each column might not sum to the column total.

those aged ≥45 years (35.5% versus 22.0%) or with a diagnosis attributed to heterosexual contact (40.7% versus 22.0%) or IDU (20.4% versus 8.6%).

Among the 46 states, a higher percentage of Hispanics or Latinos with new diagnoses resided in the South (35.4%), followed by the West (32.1%), Northeast (26.3%), and Midwest (6.2%). Characteristics of Hispanics or Latinos with a new diagnosis of HIV infection in 2010 differed regionally. Compared with other regions, the Northeast had the lowest percentage of

diagnoses in males (76.7%) and in rural residents\*\* (1.3%), whereas the South had the highest percentage in rural residents (6.0%). Although male-to-male sexual contact was the predominant transmission category for HIV infection overall (66.5%), a lower percentage of HIV infections were attributed to male-to-male sexual contact in the Northeast (52.5%). More infections were attributed to IDU in the Northeast than elsewhere (15.8% versus <8.8% in the other regions). In 2010, 48.7%

\*\* Residents of nonmetropolitan areas with <50,000 population.

of the Hispanics or Latinos in the 46 states with a diagnosis of HIV infection attributed to IDU lived in the Northeast. Among Hispanics or Latinos with new diagnoses of HIV infection who were born outside of the 50 states and the District of Columbia, Puerto Rico was the most common birthplace in the Northeast (10.6%) and Mexico in all other regions (>18.6%).

In 2010, the overall rate of new diagnoses of HIV infection among Hispanics or Latinos in 46 states was 27.6 per 100,000 persons. The rate in the Northeast (55.0) was more than twice that of any other region (Table 2).

### Prevalence Rate of Diagnosed HIV Infection

At the end of 2009, the overall prevalence rate of diagnosed HIV infection among Hispanics or Latinos was 432.3 per 100,000 persons. The prevalence rate of diagnosed HIV infection in the Northeast (1,252.6) was 3.8 times that in the South, the region with the next highest rate (333.7). Four of the five states with the highest prevalence rates of diagnosed

HIV infection per 100,000 Hispanics or Latinos at the end of 2009 were in the Northeast (Figure).

### Reported by

Qian An, MS, Angela Hernandez, MD, Joseph Prejean, PhD, Emilio J. German, MS, Horace Thompson, H. Irene Hall, PhD, Div of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC. **Corresponding contributor:** Qian An, qan@cdc.gov, 404-639-8523.

### Editorial Note

The burden of HIV infection among Hispanics or Latinos differs between the 46 states and Puerto Rico. In 2010, Hispanics or Latinos with new diagnoses of HIV infection in Puerto Rico were more likely to have HIV infection attributed to IDU or heterosexual contact and were older than those with new diagnoses in the 46 states. Within the 46 states, the Northeast region accounted for an estimated 13.9% of the Hispanic or

**TABLE 2. Estimated\* rate<sup>†</sup> of new diagnoses of HIV infection in 2010 and prevalence rate of diagnosed HIV infection at the end of 2009, among Hispanics or Latinos<sup>§</sup> aged ≥13 years, by U.S. Census region<sup>¶</sup> — 46 states**

Characteristic	Northeast		Midwest		South		West		Total	
	Rate of new diagnoses of HIV infection in 2010	Prevalence rate of diagnosed HIV infection at the end of 2009	Rate of new diagnoses of HIV infection in 2010	Prevalence rate of diagnosed HIV infection at the end of 2009	Rate of new diagnoses of HIV infection in 2010	Prevalence rate of diagnosed HIV infection at the end of 2009	Rate of new diagnoses of HIV infection in 2010	Prevalence rate of diagnosed HIV infection at the end of 2009	Rate of new diagnoses of HIV infection in 2010	Prevalence rate of diagnosed HIV infection at the end of 2009
<b>Sex</b>										
Male	83.9	1,744.3	30.1	443.2	44.2	514.3	36.3	482.6	44.7	651.6
Female	25.8	755.6	6.6	120.7	9.3	135.4	4.2	78.6	9.2	194.9
<b>Age group at diagnosis (yrs)</b>										
13–24	39.9	211.4	13.5	45.5	20.1	55.9	13.8	40.1	19.1	67.0
25–34	75.0	687.2	28.7	246.4	39.0	289.4	33.0	251.9	40.0	319.3
35–44	75.6	1,817.6	26.1	492.1	36.6	569.9	27.6	521.8	37.0	705.6
45–54	58.9	2,911.9	14.9	611.5	30.9	669.1	20.3	590.1	29.1	949.9
≥55	26.7	1,323.3	7.5	279.7	10.0	242.2	7.6	218.0	11.4	397.4
<b>Residence area at diagnosis</b>										
Urban**	55.5	1,247.5	20.7	329.4	30.6	375.2	23.5	324.2	30.6	483.0
Suburban††	47.2	1,001.5	14.3	194.9	18.3	204.0	10.2	139.5	15.9	217.4
Rural§§	31.8	1,577.6	8.5	145.1	16.4	197.6	6.0	95.6	12.7	216.0
<b>Overall¶¶</b>	<b>55.0</b>	<b>1,252.6</b>	<b>19.2</b>	<b>293.5</b>	<b>27.6</b>	<b>333.7</b>	<b>20.9</b>	<b>288.2</b>	<b>27.6</b>	<b>432.3</b>

\* Estimates resulted from statistical adjustment that accounted for reporting delays and missing risk-factor information, but not for incomplete reporting.

† Per 100,000 persons. Rates for U.S. dependent areas are not provided because U.S. Census information on race/ethnicity for U.S. dependent areas is limited. Rates are not calculated by transmission category and by place of birth because of the lack of denominator data.

§ Hispanics or Latinos can be of any race.

¶ *Northeast:* Connecticut, Maine, New Hampshire, New Jersey, New York, Pennsylvania, and Rhode Island; *Midwest:* Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin; *South:* Alabama, Arkansas, Delaware, Florida, Georgia, Kentucky, Louisiana, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, and West Virginia; *West:* Alaska, Arizona, California, Colorado, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming.

\*\* Metropolitan area of ≥500,000 population.

†† Metropolitan area of 50,000–499,999 population.

§§ Nonmetropolitan area of <50,000 population.

¶¶ Because column totals for estimated numbers were calculated independently of the values for the subpopulations, the values in each column might not sum to the column total.





### Acknowledgment

Sandra Miranda De Leon, MPH, HIV Surveillance Program,  
Puerto Rico Dept of Health.

### References

1. CDC. HIV surveillance report, 2010. Vol. 22. Atlanta, GA: US Department of Health and Human Services, CDC; 2012. Available at <http://www.cdc.gov/hiv/topics/surveillance/resources/reports>. Accessed October 5, 2012.
2. Song R, Hall HI, Frey R. Uncertainties associated with incidence estimates of HIV/AIDS diagnoses adjusted for reporting delay and risk redistribution. *Stat Med* 2005;24:453–64.
3. Harrison KM, Kajese T, Hall HI, Song R. Risk factor redistribution of the national HIV/AIDS surveillance data: an alternative approach. *Public Health Rep* 2008;123:618–27.
4. US Census Bureau. Population estimates: current estimates data. July 1, 2010. Washington, DC: US Census Bureau; 2012. Available at <http://www.census.gov/popest/data/index.html>. Accessed October 5, 2012.
5. US Census Bureau. The Hispanic population: 2010. Washington, DC: US Census Bureau; 2011. Available at <http://www.census.gov/prod/cen2010/briefs/c2010br-04.pdf>. Accessed October 5, 2012.
6. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. *N Engl J Med* 2011;365:493–505.
7. Diaz T, Buehler JW, Castro KG, et al. AIDS trends among Hispanics in the United States. *Am J Public Health* 1993;83:504–9.
8. Painter TM. Connecting the dots: when the risks of HIV/STD infection appear high but the burden of infection is not known—the case of male Latino migrants in the southern United States. *AIDS Behav* 2008; 12:213–26.
9. Office of National AIDS Policy. National HIV/AIDS strategy. Washington, DC: Office of National AIDS Policy; 2010. Available at <http://www.whitehouse.gov/administration/eop/onap/nhas>. Accessed October 10, 2012.

## Evaluation of Vaccination Recall Letter System for Medicaid-Enrolled Children Aged 19–23 Months — Montana, 2011

Reminder and recall systems alert the parents of children due (reminder) or overdue (recall) for vaccination and have been associated with increased vaccination coverage (1–3). To evaluate the potential of a state-generated recall letter to increase vaccination coverage among Montana children, the Montana Department of Public Health and Human Services (DPHHS) pilot tested a recall letter system targeted at parents of children aged 19–23 months enrolled in Montana Medicaid and not known to have completed a subset of the routinely recommended vaccination series. Data extracted from Medicaid billing records and the web-based immunization registry database (WIZRD) then in use by Montana were used to ascertain whether children were up-to-date for the study vaccination series. Of the 1,865 children enrolled in Montana Medicaid and aged 19–23 months, 878 (47%) were eligible for study participation. One recall letter was sent to parents of 438 (50%) eligible children selected randomly. A reassessment of each child's vaccination status was completed 3 months after the initial mailing. At 3 months, 32% of children whose parents were sent letters were known to have completed the study vaccination series, which was not significantly different from the 28% of children who were vaccinated but whose parents had not been sent letters. Further research is needed to determine why the recall letter had limited effectiveness in this pilot study and to develop more effective methods for increasing vaccination coverage in Montana.

The Advisory Committee on Immunization Practices recommends that children aged 0–18 months receive routine vaccinations for protection against diseases caused by 14 pathogens (4). Despite these recommendations, the National Immunization Survey reported that in 2009, for children aged 19–35 months, the estimated vaccination coverage nationally for the recommended modified series (the recommended series with *Haemophilus influenzae* type b conjugate vaccine [Hib] excluded because of a Hib shortage\*) was just over 70% and coverage varied substantially among states (5). In Montana, the estimated coverage for the recommended modified series among children aged 19–35 months was 61.7%, ranking

among the lowest 10 states. To improve vaccination coverage, the Task Force on Community Preventive Services recommends the use of reminder and recall systems (2). Vaccine reminder and recall systems alert the parents of children due or overdue for vaccinations and are effective at increasing child and adult vaccination coverage whether conducted by a health-care provider, academic center, or health department (3). The Montana DPHHS does not use a vaccine reminder and recall system of its own, relying instead on vaccine providers to contact parents of children overdue for vaccination. However, among surveyed health-care providers who provide vaccines to Montana adolescents, only 21% reported using reminder and recall systems. In response, DPHHS pilot tested a state-generated recall letter that was sent to parents of Medicaid-enrolled children aged 19–23 months and not known to be fully immunized with the study vaccination series.†

Children enrolled in Montana Medicaid with birthdates from December 2, 2008, through May 1, 2009, were assessed for coverage with the study vaccination series. For these children, data were extracted from Medicaid billing records and WIZRD and imported into the Comprehensive Clinic Assessment Software Application.§ Medicaid billing data were extracted on December 28, 2010, and included data entered through December 1, 2010. Children known to have received each of the vaccines in the study vaccination series or those with home addresses outside of Montana were excluded from study participation. The study was powered to have a 99.9% likelihood and a 72% likelihood of detecting a statistically significant difference given a 15 percentage-point difference and 6 percentage-point difference, respectively, between the intervention and control cohorts, assuming 250 children per cohort,  $\alpha = 0.05$ , and a two-sided test.

† The study vaccination series includes  $\geq 4$  doses of DTaP;  $\geq 3$  doses of IPV;  $\geq 1$  dose of MMR;  $\geq 4$  doses of Hib;  $\geq 3$  doses of HepB;  $\geq 1$  dose of VAR; and  $\geq 4$  doses of PCV.

§ Coverage for Hib vaccine for the primary series was based on receipt of  $\geq 2$  or  $\geq 3$  doses, depending on product received. The Merck Hib vaccines require a 2-dose primary series with doses at ages 2 months and 4 months, and the Sanofi Pasteur Hib vaccines require a 3-dose primary series with doses at ages 2, 4, and 6 months. Coverage for the full series, which includes the primary series and a booster dose, was based on receipt of  $\geq 3$  or  $\geq 4$  doses, depending on product received. Both Merck and Sanofi Pasteur Hib vaccines require a booster dose at ages 12–15 months (5). The number of Hib doses a child is eligible to receive is dependent upon the vaccine type, the age at series initiation, and the age at which the doses are administered. The number of PCV doses a child is eligible to receive is dependent upon the age at series initiation and the age at which the doses are administered. Therefore, children might not have been eligible to receive the number of Hib and/or PCV doses needed to be considered up-to-date for the purposes of this study.

\* The modified series, excluding *Haemophilus influenzae* type b conjugate vaccine (Hib), includes  $\geq 4$  doses of diphtheria, tetanus toxoid, and acellular pertussis vaccine (DTaP)/diphtheria and tetanus toxoids vaccine (DT)/diphtheria and tetanus toxoids and pertussis vaccine (DTP);  $\geq 3$  doses of inactivated poliovirus vaccine (IPV);  $\geq 1$  dose of measles antigen-containing vaccine (MMR);  $\geq 3$  doses of hepatitis B vaccine (HepB);  $\geq 1$  doses of varicella vaccine (VAR); and  $\geq 4$  doses of pneumococcal vaccine (PCV). Hib vaccine was excluded from national reporting of the vaccine series because of the Hib vaccine shortage that occurred during 2007–2009.

**What is already known on this topic?**

The use of reminder and recall systems by health-care providers, academic centers, and health departments has been shown to be associated with increased vaccination coverage.

**What is added by this report?**

A single, state-generated recall letter did not significantly improve vaccination coverage in a rural, underserved, and underimmunized pediatric population in Montana.

**What are the implications for public health practice?**

Users of reminder and recall systems should adapt the system for the targeted patient population. Reminder and recall systems should be evaluated regularly to determine their effectiveness and modified, if necessary.

Using the Comprehensive Clinic Assessment Software Application random number generator tool, 50% of children not known to have completed the study vaccination series on December 1, 2010, were randomly assigned to the intervention cohort. On January 21, 2011, using addresses from Montana Medicaid, a letter was mailed to the parent(s) of each child reminding them to take their child to their health-care provider to receive the missed vaccines. The letters did not include an individualized listing of the missed vaccines. The remaining 50% of children were assigned to the control cohort (i.e., no letter). Letters returned as undeliverable were resent to addresses listed in WIZRD if different from the address listed in the Medicaid database. Letters were not resent if the Medicaid and WIZRD addresses were identical. In June 2011, a reassessment of vaccination status for each child was completed using the methodology for vaccines received through April 30, 2011. Pearson's chi-square test was used to evaluate the difference in participant characteristics, vaccines received by the intervention and control cohorts, and coverage for each cohort between baseline and follow-up.

Of the 1,865 children enrolled in Montana Medicaid and aged 19–23 months by December 1, 2010, a total of 878 (47%) were eligible for study participation (Table 1). Of those, 464 (53%) were male, and the median age was 21 months. Among the participants, 184 (21%) children were classified as American Indian/Alaska Native (AI/AN). Race information was not available for the other participants. The county of residence was categorized as rural or frontier<sup>‡</sup> for 87% of participants. Among participants, 357 (41%) had not received at least one or two of the recommended vaccines. The vaccines most commonly missing were the fourth dose of diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP), which

612 (70%) participants had not received, and the fourth dose of pneumococcal vaccine (PCV), which 539 (61%) participants had not received. No significant differences existed between the intervention and control cohorts for age, sex, AI/AN classification, population density for county of residence, and number of missing vaccines. Recall letters were sent to parents of 438 (50%) children; 83 (20%) of those letters initially were returned as undeliverable, of which 45 were resent.

Three months after the single recall letter was sent, 139 (32%) of the children whose parents had been sent a recall letter had completed the study vaccination series and 125 (28%) of control children had completed the series ( $p=0.28$ ) (Table 2). For 14 (70%) of 20 vaccinations, the percentages of children who received the missing vaccine by 3 months was higher in the intervention cohort compared with the control cohort, but the difference was only statistically significant for the third and fourth doses of PCV. No significant differences were found between the cohorts for the percentage of 184 AI/AN children who completed the study vaccination series (intervention = 40.4%, control = 29.4%;  $p=0.12$ ). Likewise, no significant differences were found when cohorts were stratified by county of residence for the 110 urban children (intervention = 34.4%, control = 43.5%;  $p=0.34$ ), 537 rural children (intervention = 30.5%, control = 23.1%;  $p=0.06$ ), and 231 frontier children (intervention = 33.3%, control = 34.1%;  $p=0.9$ ). In this study, 30 recall letters would need to be sent to result in one extra child being up-to-date for the study vaccination series (95% confidence interval = 10.6–∞).

**Reported by**

*Cody L. Custis, MS, Steven D Helgerson, MD, James S. Murphy, Montana Dept of Public Health and Human Svcs. Carolyn A. Parry, MPH, Immunization Svcs Div, National Center for Immunization and Respiratory Diseases; Randall J. Nett, MD, Office of Public Health Preparedness and Response, CDC.*  
**Corresponding contributor:** *Randall J. Nett, gge5@cdc.gov, 406-444-5917.*

**Editorial Note**

The findings in this study demonstrate that a single, state-generated recall letter to parents resulted in no significant increase in vaccination coverage among predominantly rural, Medicaid-enrolled children aged 19–23 months. Of children whose parents were not sent recall letters, 28% had completed the study vaccination series at 3 months. In comparison, 32% of children whose parents had been sent letters had completed the series.

Reminder and recall systems have been shown to be effective in increasing vaccination coverage in pediatric and adult populations; for universally recommended vaccines and targeted vaccines; when conducted by a health-care provider, an

<sup>‡</sup> Frontier is defined as  $\leq 6$  persons per square mile and either  $\geq 50$  miles or 60-minute drive to essential services. Additional information is available at <http://www.raconline.org/topics/frontier/frontierfaq.php#definition>, and at [http://www.nal.usda.gov/ric/ricpubs/what\\_is\\_rural.shtml](http://www.nal.usda.gov/ric/ricpubs/what_is_rural.shtml).



TABLE 1. Participant characteristics at initiation of recall letter study among Montana Medicaid-enrolled children aged 19–23 months — Montana, 2011

Characteristic	Total		Intervention cohort		Control cohort		p-value*
	No.	(%)	No.	(%)	No.	(%)	
No. of participants <sup>†</sup>	878	(100)	438	(50)	440	(50)	
<b>Sex</b>							0.46
Male	464	(53)	237	(54)	227	(52)	
Female	414	(47)	201	(46)	213	(48)	
<b>Median age</b>	21 mos		21 mos		21 mos		
<b>American Indian/Alaska Native<sup>§</sup></b>	184	(21)	89	(20)	95	(22)	0.64
<b>County of residence<sup>¶</sup></b>							0.09
Urban	110	(13)	64	(15)	46	(10)	
Rural	537	(61)	269	(61)	268	(61)	
Frontier	231	(26)	105	(24)	126	(29)	
<b>No. of missing vaccines</b>							0.96
1–2	357	(41)	175	(40)	182	(41)	
3–5	204	(23)	101	(23)	103	(24)	
6–10	121	(14)	62	(14)	59	(13)	
11–20	196	(22)	100	(23)	96	(22)	
<b>% vaccinated with selected vaccines**</b>							
DTaP fourth dose	266	(30)	138	(32)	128	(29)	0.44
HepB third dose	523	(60)	253	(58)	270	(61)	0.28
Hib fourth dose <sup>††</sup>	424	(48)	211	(48)	213	(48)	0.94
IPV third dose	539	(61)	263	(60)	276	(63)	0.41
MMR first dose	507	(58)	246	(56)	261	(59)	0.34
PCV fourth dose <sup>§§</sup>	339	(39)	170	(39)	169	(38)	0.90
VAR first dose	459	(52)	221	(50)	238	(54)	0.28

**Abbreviations:** DTaP = diphtheria, tetanus toxoid, and acellular pertussis vaccine; HepB = hepatitis B vaccine; Hib = *Haemophilus influenzae* type b conjugate vaccine; IPV = inactivated poliovirus vaccine; MMR = measles, mumps, and rubella vaccine; PCV = pneumococcal vaccine; VAR = varicella vaccine.

\* p-value calculated using chi-square test.

<sup>†</sup> Children living in Montana, enrolled in Montana Medicaid, with birthdates December 2, 2008–May 1, 2009, and not known to have received each of the following:  $\geq 4$  doses of DTaP;  $\geq 3$  doses of IPV;  $\geq 1$  dose of MMR;  $\geq 4$  doses of Hib;  $\geq 3$  doses of HepB;  $\geq 1$  dose of VAR; and  $\geq 4$  doses of PCV.

<sup>§</sup> Data for other race classifications were not available.

<sup>¶</sup> Categories based on U.S. Department of Agriculture descriptions, available at [http://www.nal.usda.gov/ric/ricpubs/what\\_is\\_rural.shtml](http://www.nal.usda.gov/ric/ricpubs/what_is_rural.shtml).

\*\* The individual vaccines in this analysis represent the last possible dose in the selected vaccine's series that can be administered to a child aged 18 months.

<sup>††</sup> Coverage for Hib vaccine for the primary series was based on receipt of  $\geq 2$  or  $\geq 3$  doses, depending on product received. The Merck Hib vaccines require a 2-dose primary series with doses at ages 2 months and 4 months, and the Sanofi Pasteur Hib vaccines require a 3-dose primary series with doses at ages 2, 4, and 6 months. Coverage for the full series, which includes the primary series and a booster dose, was based on receipt of  $\geq 3$  or  $\geq 4$  doses, depending on product received. The Merck and Sanofi Pasteur Hib vaccines require a booster dose at ages 12–15 months. The number of Hib doses a child is eligible to receive depends on the vaccine type, the age at series initiation, and the age at which the doses are administered. Therefore, children might not have been eligible to receive the number of Hib doses needed to be considered up-to-date for this study.

<sup>§§</sup> The number of PCV doses a child is eligible to receive depends on the age at series initiation and the age at which the doses are administered. Therefore, children might not have been eligible to receive the number of doses needed to be considered up-to-date for this study.

academic center, or a health department; and, when carried out using postcards, mailed letters, or telephone calls (3,6). However, as found in this study, specific reminder and recall systems and methods are not effective in every setting. For example, among urban adolescent populations, text message reminders have been shown to significantly increase vaccination coverage while automated telephone messages have not (7,8).

Previous studies have shown the effectiveness of certain reminder and recall systems in rural settings. Reminder postcards were effective in improving vaccination coverage among a predominantly low-income, rural, and Latino pediatric population (9). That study differed from the investigation presented here in that the population was predominantly Hispanic, the system was community health center-based, and multiple mailings were used. In another study, automated telephone reminders and recalls conducted by rural county health

departments in Georgia were effective at increasing immunization visits (6). Unlike the Montana investigation, the Georgia study used multiple attempts until contact was made with the parent. These findings highlight the importance of the exact methods chosen to implement a reminder and recall system.

Selecting the method most likely to be effective in a particular community might require pilot testing and an evaluation of the results. The findings of this investigation suggest that studies conducted in suburban and urban areas might not predict the success of interventions implemented in rural areas and certain types of reminder and recall systems might not be effective in rural settings. Compared with urban populations, rural populations are likely to be less educated, less affluent, and have less access to transportation (10); these factors and others might influence childhood vaccination coverage and the effectiveness of certain vaccine reminder and recall methods.

**TABLE 2. Children eligible to receive the study vaccination series\* and individual vaccines at baseline and number of eligible children vaccinated at 3 months following the mailing of a vaccine recall letter to parents of Montana Medicaid-enrolled children aged 19–23 months† — Montana, 2011**

Study vaccination series	Intervention cohort			Control cohort			Odds ratio	(95% CI)
	Eligible to receive vaccine at baseline	Eligible children vaccinated at 3 mos		Eligible to receive vaccine at baseline	Eligible children vaccinated at 3 mos			
	No.	No.	(%)	No.	No.	(%)		
<b>Participants</b>	438	139	(32)	440	125	(28)	1.2	(0.9–1.6)
<b>DTaP</b>								
First dose	63	14	(22)	63	14	(22)	1.0	(0.4–2.3)
Second dose	101	22	(22)	93	16	(17)	1.3	(0.7–2.7)
Third dose	151	44	(29)	140	28	(20)	1.7	(1.0–2.8)
Fourth dose	300	101	(34)	312	102	(33)	1.0	(0.7–1.5)
<b>HepB</b>								
First dose	70	11	(16)	57	14	(25)	0.6	(0.2–1.4)
Second dose	104	37	(36)	87	39	(45)	0.7	(0.4–1.2)
Third dose	185	95	(51)	170	90	(53)	0.9	(0.6–1.4)
<b>Hib<sup>§</sup></b>								
First dose	72	15	(21)	68	12	(18)	1.2	(0.5–2.9)
Second dose	91	11	(12)	95	12	(13)	1.0	(0.4–2.3)
Third dose	148	43	(29)	146	35	(24)	1.3	(0.8–2.2)
Fourth dose	227	47	(21)	227	39	(17)	1.3	(0.8–2.0)
<b>IPV</b>								
First dose	76	14	(18)	69	13	(19)	1.0	(0.4–2.2)
Second dose	106	25	(24)	102	19	(19)	1.3	(0.7–2.6)
Third dose	175	51	(29)	164	35	(21)	1.5	(0.9–2.5)
<b>MMR</b>								
First dose	192	60	(31)	179	50	(28)	1.2	(0.8–1.8)
<b>PCV<sup>¶</sup></b>								
First dose	86	18	(21)	79	13	(16)	1.3	(0.6–3.0)
Second dose	110	24	(22)	107	16	(15)	1.6	(0.8–3.2)
Third dose	170	51	(30)	157	29	(18)	1.9	(1.1–3.2)
Fourth dose	268	49	(18)	271	26	(10)	2.1	(1.3–3.5)
<b>VAR</b>								
First dose	217	62	(29)	202	47	(23)	1.3	(0.9–2.0)

**Abbreviations:** DTaP = diphtheria, tetanus toxoid, and acellular pertussis vaccine; HepB = hepatitis B vaccine; Hib = *Haemophilus influenzae* type b conjugate vaccine; IPV = inactivated poliovirus vaccine; MMR = measles, mumps, and rubella vaccine; PCV = pneumococcal vaccine; VAR = varicella vaccine; CI = confidence interval.

\* The study vaccination series includes ≥4 doses of diphtheria, tetanus toxoid, and acellular pertussis vaccine (DTaP); ≥3 doses of inactivated poliovirus vaccine (IPV); ≥1 dose of measles, mumps, and rubella vaccine (MMR); ≥4 doses of *Haemophilus influenzae* type b conjugate vaccine (Hib); ≥3 doses of hepatitis B vaccine (HepB); ≥1 dose of varicella vaccine (VAR); and ≥4 doses of pneumococcal vaccine (PCV).

† Children living in Montana, enrolled in Montana Medicaid, with birthdates December 2, 2008–May 1, 2009, and not known to have received each of the following: ≥4 doses of DTaP; ≥3 doses of IPV; ≥1 dose of MMR; ≥4 doses of Hib; ≥3 doses of HepB; ≥1 dose of VAR; and ≥4 doses of PCV.

§ Coverage for Hib vaccine for the primary series was based on receipt of ≥2 or ≥3 doses, depending on product type received. The Merck Hib vaccines require a 2-dose primary series with doses at ages 2 months and 4 months, and the Sanofi Pasteur Hib vaccines require a 3-dose primary series with doses at ages 2, 4, and 6 months. Coverage for the full series, which includes the primary series and a booster dose, was based on receipt of ≥3 or ≥4 doses, depending on product type received. The Merck and Sanofi Pasteur Hib vaccines require a booster dose at ages 12–15 months. The number of Hib doses a child is eligible to receive depends on the vaccine type, the age at series initiation, and the age at which the doses are administered. Therefore, children might not have been eligible to receive the number of Hib doses needed to be considered up-to-date for this study.

¶ The number of PCV doses a child is eligible to receive depends on the age at series initiation and the age at which the doses are administered. Therefore, children might not have been eligible to receive the number of doses needed to be considered up-to-date for this study.

The findings in this report are subject to at least seven limitations. First, recall letters were not sent by certified mail; therefore, no confirmation that the intended recipients received the letters was obtained. A low percentage of successfully delivered letters might diminish the difference in vaccination coverage between the intervention and control cohorts. Second, an average delay of 4 weeks occurs between administration of a vaccine

and Montana Medicaid's receipt of the health-care provider's billing statement. However, health-care providers have up to 1 year to bill Medicaid for vaccines administered, so delays in billing for some vaccines might hide some differences in vaccination coverage between intervention and control cohorts. Third, only 93% of public health-care providers and 74% of private health-care providers are known to be active users of

WIZRD (DPHHS, unpublished data, 2011). Therefore, the immunization rates presented in this study might be underestimated. Fourth, children with delayed initiation of the PCV or Hib series might have been eligible to receive fewer doses of those vaccines and thus be considered up-to-date per Advisory Committee on Immunization Practices recommendations but underimmunized for PCV or Hib for this study. Fifth, only a single recall letter was sent; the use of multiple letters might have resulted in higher vaccination coverage. Sixth, the children sent letters might have differed from the children not sent letters regarding certain factors that were not assessed; these factors might have diminished the impact of the letters in increasing vaccination coverage. Finally, the medical records of study participants were not available for review; thus, the completeness of the vaccination status for each child cannot be confirmed.

This intervention aimed at increasing vaccination coverage among children enrolled in Montana Medicaid by mailing a single, state-generated vaccine recall letter to their parents resulted in no significant increase in vaccination coverage of their children. Based on these findings and a review of the literature, 1) health-care providers should use reminder and recall systems to improve vaccination coverage among their patients (1,2); 2) state and local health departments should use the reminder and recall system(s) most likely to improve vaccination coverage in their population; 3) users of reminder and recall systems should evaluate their system to determine its effectiveness and adjust their strategy as needed to improve system performance; and 4) public health authorities should conduct further research to identify effective reminder and recall system(s) for improving vaccination coverage, particularly in rural underserved areas.

## Acknowledgments

Carol Ballew, PhD, Eric Higginbotham, Bekki Wehner, Kathleen Grady, Vicci Stroop, Heather Zimmerman, MPH, Montana Dept of Public Health and Human Svcs.

## References

1. CDC. Recommendations of the Advisory Committee on Immunization Practices, the American Academy of Pediatrics, and the American Academy of Family Physicians: use of reminder and recall by vaccination providers to increase vaccination rates. *MMWR* 1998;47:715–7.
2. CDC. Vaccine-preventable diseases: improving vaccination coverage in children, adolescents, and adults. A report on recommendations from the Task Force on Community Preventive Services. *MMWR* 1999; 48(No. RR-8).
3. Jacobson VJ, Szilagyi P. Patient reminder and patient recall systems to improve immunization rates. *Cochrane Database Syst Rev* 2005(3): CD003941.
4. CDC. General recommendations on immunization—recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR* 2011;60(No. RR-2).
5. CDC. National, state, and local area vaccination coverage among children aged 19–35 months—United States, 2009. *MMWR* 2010;59:1171–7.
6. Linkins RW, Dini EF, Watson G, Patriarca PA. A randomized trial of the effectiveness of computer-generated telephone messages in increasing immunization visits among preschool children. *Arch Pediatr Adolesc Med* 1994;148:908–14.
7. Stockwell MS, Karbanda EO, Martinez RA, et al. Text4Health: impact of text message reminder-recalls for pediatric and adolescent immunizations. *Am J Public Health* 2012;102:e15–21.
8. Szilagyi PG, Schaffer S, Barth R, et al. Effect of telephone reminder/recall on adolescent immunization and preventive visits: results from a randomized clinical trial. *Arch Pediatr Adolesc Med* 2006;160:157–63.
9. Hicks P, Tarr GA, Hicks XP. Reminder cards and immunization rates among Latinos and the rural poor in northeast Colorado. *J Am Board Fam Med* 2007;20:581–6.
10. National Organization of State Offices of Rural Health. National rural health issues. Sterling Heights, MI: National Organization of State Offices of Rural Health; 2006. Available at [http://www.nosorh.org/pdf/Rural\\_Impact\\_Study\\_States\\_IT.pdf](http://www.nosorh.org/pdf/Rural_Impact_Study_States_IT.pdf). Accessed October 10, 2012.

## Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP)

On June 20, 2012, the Advisory Committee on Immunization Practices (ACIP) recommended routine use of 13-valent pneumococcal conjugate vaccine (PCV13; Prevnar 13, Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer, Inc.) for adults aged  $\geq 19$  years with immunocompromising conditions, functional or anatomic asplenia, cerebrospinal fluid (CSF) leaks, or cochlear implants (Table). PCV13 should be administered to eligible adults in addition to the 23-valent pneumococcal polysaccharide vaccine (PPSV23; Pneumovax 23, Merck & Co. Inc.), the vaccine currently recommended for these groups of adults (1). The evidence for the benefits and risk of PCV13 vaccination of adults with immunocompromising conditions was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework and designated as a Category A recommendation (2,3). This report outlines the new ACIP recommendations for PCV13 use; explains the recommendations for the use of PCV13 and PPSV23 among adults with immunocompromising conditions, functional or anatomic asplenia, CSF leaks, or cochlear implants; and summarizes the evidence considered by ACIP to make its recommendations.

### Epidemiology of Pneumococcal Infection in Immunocompromised Adults

*Streptococcus pneumoniae* (pneumococcus) remains a leading cause of serious illness, including bacteremia, meningitis, and

Recommendations for routine use of vaccines in children and adolescents are developed by the Advisory Committee on Immunization Practices (ACIP). ACIP is chartered as a federal advisory committee to provide expert external advice and guidance to the Director of CDC on use of vaccines in the civilian population of the United States. Recommendations are harmonized to the greatest extent possible with recommendations made by the American Academy of Pediatrics (AAP), the American Academy of Family Physicians (AAFP), and the American College of Obstetrics and Gynecology (ACOG). Recommendations for routine use of vaccines in adults are harmonized with recommendations of AAFP, ACOG, and the American College of Physicians. ACIP recommendations adopted by the Director of CDC become recommendations of the agency on the date published in *MMWR*.

pneumonia among adults in the United States. An estimated 4,000 deaths occur in the United States each year because of *S. pneumoniae*, primarily among adults (4). The incidence of invasive disease ranges from 3.8 per 100,000 among persons aged 18–34 years to 36.4 per 100,000 among those aged  $\geq 65$  years (4). Adults with certain medical conditions also are at increased risk for invasive pneumococcal disease (IPD). For adults aged 18–64 years with hematologic cancer, the rate of IPD in 2010 was 186 per 100,000, and for persons with human immunodeficiency virus (HIV) the rate was 173 per 100,000 (CDC, unpublished data, 2012). The disease rates for adults in these groups can be more than 20 times those for adults without high-risk medical conditions.

PCV13 has been used for children since 2010, when it replaced an earlier version targeting seven serotypes (PCV7; Prevnar, Pfizer) that had been in use since 2000. The routine use of PCV7 in infants and young children resulted in significant reductions in IPD caused by vaccine serotypes in children, and because of indirect effects, also in adults. Rates of IPD caused by vaccine serotypes in adults aged 18–64 years without HIV decreased from six cases to one case per 100,000 during 2000–2007. However, even after indirect effects of the pediatric immunization had been realized fully, the incidence of IPD caused by the serotypes included in PCV7 remained high in HIV-infected persons aged 18–64 years at 64 cases per 100,000 persons with acquired immunodeficiency syndrome (AIDS) (5). Moreover, 50% of IPD cases among immunocompromised adults in 2010 were caused by serotypes contained in PCV13; an additional 21% were caused by serotypes only contained in PPSV23 (CDC, unpublished data, 2011).

### PCV13 Vaccine in Adults

PCV13 was licensed by the Food and Drug Administration (FDA) for prevention of IPD and otitis media in infants and young children in February 2010, supplanting PCV7 (6). PCV13 is identical in formulation for the seven common serotypes in PCV7, but it includes six additional antigens. One dose of PCV13 is recommended by ACIP for children aged 6–18 years with high-risk conditions such as functional or anatomic asplenia, immunocompromising conditions, cochlear implants, or CSF leaks. In December 2011, FDA licensed PCV13 for prevention of pneumonia and IPD in adults aged  $\geq 50$  years (7). The license for adult use was granted under FDA's



accelerated approval pathway, which allows the agency to approve products for serious or life-threatening diseases on the basis of early evidence of a product's effectiveness that is reasonably likely to predict clinical benefit. Approval of PCV13 for adults was based on immunogenicity studies that compared antibody responses to PCV13 with antibody responses to PPSV23 (7).

In two randomized, multicenter immunogenicity studies conducted in the United States and Europe, immunocompetent adults aged  $\geq 50$  years received a single dose of PCV13 or PPSV23 (8). In adults aged 60–64 years and aged  $>70$  years, PCV13 elicited opsonophagocytic activity (OPA) geometric mean antibody titers (GMTs) that were comparable with, or higher than, responses elicited by PPSV23. OPA GMTs elicited by PCV13 in adults aged 50–59 years for all 13 serotypes were comparable with the corresponding GMTs elicited by administration of PCV13 in adults aged 60–64 years. Persons who received PPSV23 as the initial study dose had lower opsonophagocytic antibody responses after subsequent administration of a PCV13 dose 1 year later than those who had received PCV13 as the initial dose (8). Data on the immunogenicity of PCV13 in immunocompromised adults are not available.

Safety of PCV13 was evaluated in approximately 6,000 PPSV23-naïve and PPSV23-experienced adults aged  $\geq 50$  years (8). Overall incidence of serious adverse events reported within 1 month of an initial study dose was  $<2\%$  for both vaccines, with no significant differences between treatment groups. Common adverse reactions reported with PCV13 were pain, redness, and swelling at the injection site; limitation of movement of the injected arm; fatigue; and headache (8). Safety studies presented for licensure did not enroll immunocompromised subjects.

Although clinical trial data are not yet available for PCV13, a randomized, controlled trial of PCV7 efficacy among 496 HIV-infected adults in Malawi demonstrated vaccine efficacy of 75% (95% confidence interval = 29%–92%) in preventing IPD (9). The study population differed from the general U.S. HIV-infected population, however, in that all participants had survived a previous episode of IPD, only 13% were on antiretrovirals, and the all-cause mortality rate was  $>25\%$ . The number of serious adverse events within 14 days after vaccination was significantly lower (three versus 17;  $p=0.002$ ) in the vaccine group (248 persons) than in the placebo group (248 persons), whereas minor adverse events were significantly more common in the vaccine group (41 versus 13;  $p=0.003$ ) (9).

Four studies of PCV7 immunogenicity involving 699 HIV-infected subjects, all with CD4 counts of  $>200$  cells/ $\mu\text{L}$ , were conducted in the United States and Europe. Antibody response to a single dose of PCV7 was comparable with PPSV23 for the serotypes evaluated, at all times studied (10–13). When PPSV23 and PCV7 were administered in series, greater immune response was demonstrated when PCV7 was given

first (8,11). None of the studies were designed to evaluate the optimal interval between doses; however, in another study, no evidence of blunting of an immune response to PCV7 was observed when a dose of PPSV23 was given 5 years (range: 3.5–6.6 years) before a dose of PCV7 (14).

### PPSV23 Vaccine

PPSV23 contains 12 of the serotypes included in PCV13, plus 11 additional serotypes. PPSV23 is recommended for prevention of IPD among all adults aged  $\geq 65$  years, and for adults at high risk aged 19–64 years (1,3). Although conflicting evidence regarding PPSV23 efficacy in HIV-infected adults has been published (15,16), the GRADE evaluation reviewed by ACIP concluded that potential benefits from PPSV23 use in this population outweigh any potential harms. Given the high burden of IPD caused by serotypes in PPSV23 but not in PCV13, broader protection might be provided through use of both pneumococcal vaccines.

The current ACIP PPSV23 recommendations call for vaccination of adults at high risk aged 19–64 years at the time of diagnosis of the high-risk condition. A one-time revaccination dose of PPSV23 is recommended 5 years after the first dose for persons with functional or anatomic asplenia and for immunocompromised persons (Table). All adults are eligible for a dose of PPSV23 at age 65 years, regardless of previous PPSV23 vaccination; however, a minimum interval of 5 years between PPSV23 doses should be maintained (1).

### Cost-Effectiveness

A cost-effectiveness analysis was performed using a lifetime cohort model of an implemented vaccine program wherein persons with selected immunocompromising conditions were immunized with PCV13 at the time of diagnosis and then followed current PPSV23 vaccination guidelines starting 1 year later. PCV13 vaccine efficacy against IPD and pneumonia (used as a proxy for effectiveness in the model) was 75% and 13%, respectively, for persons with HIV/AIDS and persons requiring dialysis, and 25% and 0%, respectively, for persons with hematologic cancer and for organ transplant recipients. Using the current costs of PCV13, PPSV23, and administration, the modeled program resulted in a cost saving of \$7,600,000, added 1,360 quality-adjusted life years, and averted 57 cases of IPD (CDC, unpublished data, 2012). These savings accrued largely as a result of protection among patients on dialysis and those with HIV/AIDS. Heterogeneity across risk groups was driven by differences in pneumococcal serotypes causing disease and assumed vaccine efficacy in each subgroup. The model was sensitive to assumptions about vaccine efficacy, whereby increased estimation of PCV13 efficacy led to increases in cost-effectiveness.

## ACIP Recommendations for PCV13 and PPSV23 Use

Adults with specified immunocompromising conditions who are eligible for pneumococcal vaccine should be vaccinated with PCV13 during their next pneumococcal vaccination opportunity.

**Pneumococcal vaccine-naïve persons.** ACIP recommends that adults aged  $\geq 19$  years with immunocompromising conditions, functional or anatomic asplenia, CSF leaks, or cochlear implants, and who have not previously received PCV13 or PPSV23, should receive a dose of PCV13 first, followed by a dose of PPSV23 at least 8 weeks later (Table). Subsequent doses of PPSV23 should follow current PPSV23 recommendations for adults at high risk. Specifically, a second PPSV23 dose is recommended 5 years after the first PPSV23 dose for persons aged 19–64 years with functional or anatomic asplenia and for persons with immunocompromising conditions. Additionally, those who received PPSV23 before age 65 years for any indication should receive another dose of the vaccine at age 65 years, or later if at least 5 years have elapsed since their previous PPSV23 dose.

**Previous vaccination with PPSV23.** Adults aged  $\geq 19$  years with immunocompromising conditions, functional or anatomic

asplenia, CSF leaks, or cochlear implants, who previously have received  $\geq 1$  doses of PPSV23 should be given a PCV13 dose  $\geq 1$  year after the last PPSV23 dose was received. For those who require additional doses of PPSV23, the first such dose should be given no sooner than 8 weeks after PCV13 and at least 5 years after the most recent dose of PPSV23.

### Reported by

Nancy M. Bennett, MD, Advisory Committee on Immunization Practices Pneumococcal Work Group. Cynthia G. Whitney, MD, Matt Moore, MD, Tamara Pilishvili, MPH, Respiratory Diseases Br, Div of Bacterial Diseases, National Center for Immunization and Respiratory Diseases; Kathleen L. Dooling, MD, EIS Officer, CDC. **Corresponding contributor:** Tamara Pilishvili, [tdp4@cdc.gov](mailto:tdp4@cdc.gov), 404-639-3585.

### Acknowledgments

Members of the Advisory Committee on Immunization Practices; member roster for July 2011–June 2012 available at <http://www.cdc.gov/vaccines/acip/committee/members-archive/members-07-2011-06-2012.html>.

**TABLE. Medical conditions or other indications for administration of 13-valent pneumococcal conjugate vaccine (PCV13), and indications for 23-valent pneumococcal polysaccharide vaccine (PPSV23) administration and revaccination for adults aged  $\geq 19$  years,\* by risk group — Advisory Committee on Immunization Practices, United States, 2012**

Risk group	Underlying medical condition	PPSV23		
		PCV13	Recommended	Revaccination 5 yrs after first dose
Immunocompetent persons	Chronic heart disease <sup>†</sup>		✓	
	Chronic lung disease <sup>§</sup>		✓	
	Diabetes mellitus		✓	
	Cerebrospinal fluid leak	✓	✓	
	Cochlear implant	✓	✓	
	Alcoholism		✓	
	Chronic liver disease, cirrhosis		✓	
	Cigarette smoking		✓	
Persons with functional or anatomic asplenia	Sickle cell disease/other hemoglobinopathy	✓	✓	✓
	Congenital or acquired asplenia	✓	✓	✓
Immunocompromised persons	Congenital or acquired immunodeficiency <sup>¶</sup>	✓	✓	✓
	Human immunodeficiency virus infection	✓	✓	✓
	Chronic renal failure	✓	✓	✓
	Nephrotic syndrome	✓	✓	✓
	Leukemia	✓	✓	✓
	Lymphoma	✓	✓	✓
	Hodgkin disease	✓	✓	✓
	Generalized malignancy	✓	✓	✓
	Iatrogenic immunosuppression**	✓	✓	✓
	Solid organ transplant	✓	✓	✓
	Multiple myeloma	✓	✓	✓

\* All adults aged  $\geq 65$  years should receive a dose of PPSV23, regardless of previous history of vaccination with pneumococcal vaccine.

<sup>†</sup> Including congestive heart failure and cardiomyopathies, excluding hypertension.

<sup>§</sup> Including chronic obstructive pulmonary disease, emphysema, and asthma.

<sup>¶</sup> Includes B- (humoral) or T-lymphocyte deficiency, complement deficiencies (particularly C1, C2, C3, and C4 deficiencies), and phagocytic disorders (excluding chronic granulomatous disease).

\*\* Diseases requiring treatment with immunosuppressive drugs, including long-term systemic corticosteroids and radiation therapy.

## References

1. CDC. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). *MMWR* 2010;59:1102–6.
2. Ahmed F, Temte JL, Campos-Outcalt D, Schünemann HJ; ACIP Evidence Based Recommendations Work Group (EBRWG). Methods for developing evidence-based recommendations by the Advisory Committee on Immunization Practices (ACIP) of the U.S. Centers for Disease Control and Prevention (CDC). *Vaccine* 2011;29:9171–6.
3. CDC. ACIP GRADE tables, 2012. Atlanta, GA: US Department of Health and Human Services, CDC; 2012. Available at <http://www.cdc.gov/vaccines/acip/recs/GRADE/pneumo-immuno-adults.html>. Accessed October 10, 2012.
4. CDC. Active Bacterial Core surveillance report, Emerging Infections Program Network, *Streptococcus pneumoniae*, 2010. Atlanta, GA: US Department of Health and Human Services, CDC; 2011. Available at <http://www.cdc.gov/abcs/reports-findings/survreports/spneu10-orig.html>. Accessed October 1, 2012.
5. Cohen AL, Harrison LH, Farley MM, et al. Prevention of invasive pneumococcal disease among HIV-infected adults in the era of childhood pneumococcal immunization. *AIDS* 2010;24:2253–62.
6. CDC. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children—Advisory Committee on Immunization Practices (ACIP), 2010. *MMWR* 2010; 59:258–61.
7. Food and Drug Administration. FDA expands use of Prevnar 13 vaccine for people ages 50 and older. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2011. Available at <http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm285431.htm>. Accessed October 10, 2012.
8. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee (VRBPAC) adult indication briefing document: Prevnar 13. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2011. Available at <http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/bloodvaccinesandotherbiologics/vaccinesandrelatedbiologicalproducts/advisorycommittee/ucm279680.pdf>. Accessed October 10, 2012.
9. French N, Gordon SB, Mwalukomo T, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. *N Engl J Med* 2010;362:812–22.
10. Feikin DR, Elie CM, Goetz MB, et al. Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults. *Vaccine* 2002;20:545–53.
11. Lesprit P, Pédrone G, Molina JM, et al. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. *AIDS* 2007;21:2425–34.
12. Peñaranda M, Payeras A, Cambra A, et al. Conjugate and polysaccharide pneumococcal vaccines do not improve initial response of the polysaccharide vaccine in HIV-infected adults. *AIDS* 2010;24:1226–8.
13. Crum-Cianflone NF, Huppler Hullsiek K, Roediger M, et al. A randomized clinical trial comparing revaccination with pneumococcal conjugate vaccine to polysaccharide vaccine among HIV-infected adults. *J Infect Dis* 2010;202:1114–25.
14. Miiro G, Kayhty H, Watera C, et al. Conjugate pneumococcal vaccine in HIV-infected Ugandans and the effect of past receipt of polysaccharide vaccine. *J Infect Dis* 2005;192:1801–5.
15. French N, Nakiyingi J, Carpenter LM, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. *Lancet* 2000;355:2106–11.
16. Breiman RF, Keller DW, Phelan MA, et al. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients. *Arch Intern Med* 2000;160:2633–8.

## Severe Respiratory Illness Associated with a Novel Coronavirus — Saudi Arabia and Qatar, 2012

On October 4, 2012, this report was posted as an MMWR Early Release on the MMWR website (<http://www.cdc.gov/mmwr>).

CDC is working closely with the World Health Organization (WHO) and other partners to better understand the public health risk presented by a recently detected, novel coronavirus. This virus has been identified in two patients, both previously healthy adults who suffered severe respiratory illness (1,2). The first patient, a man aged 60 years from Saudi Arabia, was hospitalized in June 2012 and died; the second patient, a man aged 49 years from Qatar with onset of symptoms in September 2012 was transported to the United Kingdom for intensive care. He remains hospitalized on life support with both pulmonary and renal failure (3,4). Person-to-person or health-care-associated transmission has not been identified to date (5). Interim case definitions based on acute respiratory illness and travel history were issued by WHO on September 29 and include criteria for “patient under investigation,” “probable case,” and “confirmed case” (6). This information is current as of October 4. Updates on the investigation and the WHO case definition are available at <http://www.who.int/csr/don/en/index.html>.

Coronaviruses are a large, diverse group of viruses that affect many animal species. A few of these viruses cause a wide range of respiratory illness in humans, typically with “common cold” symptoms. Genetic sequence data indicate that this new virus is a beta-coronavirus similar to bat coronaviruses, but not similar to any other coronavirus previously described in humans, including the coronavirus that caused severe acute respiratory syndrome (SARS) (1). Comparison of viral genetic sequences from the two patients indicated that the two viruses are closely related. Treatment is supportive because no specific therapy has been shown to be effective.

WHO and CDC have not issued any travel alerts at this time. The risk to U.S. residents traveling in the region currently is estimated to be low. For persons traveling to Saudi Arabia to participate in the Hajj, scheduled for October 24–29, 2012, requirements and recommendations remain unchanged and can be found at <http://www.cdc.gov/features/Hajj>.

Persons who develop acute respiratory illness within 10 days after returning from Saudi Arabia or Qatar (excluding persons who only passed through airports) should consult a physician and mention their recent travel. Persons with acute severe lower respiratory illness requiring hospitalization should be evaluated using the guidance at the CDC coronavirus website

(<http://www.cdc.gov/coronavirus/ncv>), which is based on the WHO case definition. Persons whose respiratory illness remains unexplained and who meet the WHO criteria for “patient under investigation” should be reported immediately to CDC through state and local health departments. At present, testing of specimens for the novel coronavirus will be conducted by CDC; widely available diagnostic tests for coronaviruses are not suitable for detecting this new virus.

Recommendations and guidance on the case definitions, infection control including personal protective equipment, case investigation, and specimen collection and shipment, are available at the CDC coronavirus website. Because of the possibility of frequent updates as new information becomes available, readers are encouraged to consult the CDC coronavirus website for current information. State and local health departments with questions should contact the CDC Emergency Operations Center (770-488-7100).

### Reported by

*Div of Viral Diseases, National Center for Immunization and Respiratory Diseases; Div of Healthcare Quality Promotion, Div of Global Migration and Quarantine, National Center for Emerging and Zoonotic Infectious Diseases; Div of Global Disease Detection and Emergency Response, Center for Global Health; Eyal Leshem, MD, EIS Officer, CDC. Corresponding contributor: Eyal Leshem, [eleshem@cdc.gov](mailto:eleshem@cdc.gov), 404-639-7251.*

### References

1. Corman VM, Eckerle I, Bleicker T, et al. Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. *Euro Surveill* 2012;17(39).
2. Danielsson N, on behalf of the ECDC Internal Response Team, Catchpole M. Novel coronavirus associated with severe respiratory disease: case definition and public health measures. *Euro Surveill* 2012;17(39).
3. Bermingham A, Chand MA, Brown CS, et al. Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. *Euro Surveill* 2012;17(40).
4. European Centre for Disease Prevention and Control (ECDC). Rapid risk assessment: severe respiratory disease associated with a novel coronavirus. Stockholm, Sweden: ECDC; 2012. Available at <http://ecdc.europa.eu/en/publications/Publications/RRA-Novel-coronavirus-final20120924.pdf>. Accessed October 4, 2012.
5. Pebody RG, Chand MA, Thomas HL, et al. The United Kingdom public health response to an imported laboratory confirmed case of a novel coronavirus in September 2012. *Euro Surveill* 2012;17(40).
6. World Health Organization. Global alert and response (GAR): revised interim case definition—novel coronavirus. Geneva, Switzerland: World Health Organization; 2012. Available at [http://www.who.int/csr/disease/coronavirus\\_infections/case\\_definition/en/index.html](http://www.who.int/csr/disease/coronavirus_infections/case_definition/en/index.html). Accessed October 4, 2012.



## Announcements

### World Arthritis Day 2012

October 12, 2012, is World Arthritis Day. Started in 1996, World Arthritis Day serves as a focus for organizations and individuals to work toward increasing awareness of arthritis and other rheumatic conditions worldwide. In the United States, 50 million adults and 300,000 children have some form of arthritis or other rheumatic condition (1). Arthritis is the most common cause of disability in the United States (2). By 2030, CDC projects that 67 million persons will be affected by arthritis, and among those, 25 million will be limited in their usual activities (3).

This year's theme is "Move to Improve." For persons with arthritis, aerobic and muscle strengthening exercises can reduce pain; improve mobility, function, and mood; and delay disability, helping them to stay independent, keep working, and participate in valued social activities (4). Physical activity also can help persons with arthritis to manage their other chronic conditions, such as heart disease, diabetes, and obesity. Low impact, moderate intensity activities such as walking, cycling, water exercise, and fitness classes are safe and effective for persons with arthritis. The current recommendation for adults, including those with arthritis, is 150 minutes (2.5 hours) of moderate intensity physical activity per week. That can be achieved with 30 minutes of activity at least 5 days per week. Activity can be broken into 10–15 minute sessions and spread throughout the day.

CDC funds 12 state health departments to implement and disseminate physical activity, self-management education, and health communications campaigns targeting adults with arthritis. During 2008–2011, these 12 states delivered evidence-based self-management education or physical activity programs to >132,000 persons with arthritis. Additional information on World Arthritis Day is available at <http://www.worldarthritisday.org>.

#### References

1. CDC. Prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation—United States, 2007–2009. *MMWR* 2010;59:1261–5.
2. CDC. Prevalence and most common causes of disability among adults—United States, 2005. *MMWR* 2009;58:421–6.
3. Hootman JM, Helmick CG. Projections of US prevalence of arthritis and associated activity limitations. *Arth Rheum* 2006;54:226–9.
4. US Department of Health and Human Services. Physical Activity Guidelines Advisory Committee report, 2008. Washington, DC: US Department of Health and Human Services; 2008. Available at <http://www.health.gov/paguidelines/committeereport.aspx>. Accessed August 28, 2012.

### Global Handwashing Day — October 15, 2012

The fifth annual Global Handwashing Day will be observed on October 15, 2012. This observance increases awareness and understanding of handwashing with soap as an effective and affordable method of preventing disease around the world.

Handwashing with soap has an important role to play in child survival and health. About 2.2 million children aged <5 years die each year from diarrheal diseases or pneumonia, the top two killers of young children worldwide (1). Handwashing is not only simple and inexpensive, but handwashing with soap can reduce the incidence of diarrhea by 30% (2) and respiratory infections by 21% (3) among children aged <5 years.

Although persons around the world clean their hands with water, very few use soap to wash their hands. Washing hands with soap removes bacteria much more effectively (4).

Additional information on Global Handwashing Day is available from CDC at <http://www.cdc.gov/features/globalhandwashing>. General handwashing information is available at <http://www.cdc.gov/handwashing>. Information on water-related hygiene is available at <http://www.cdc.gov/healthywater/hygiene/index.html>.


#### References

1. Liu L, Johnson HL, Cousens S, et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. *Lancet* 2012;379:2151–61.
2. Ejemot RI, Ehiri JE, Meremikwu MM, Critchley JA. Hand washing for preventing diarrhoea. *Cochrane Database Syst Rev* 2008;(1):CD004265.
3. Aiello AE, Coulborn RM, Perez V, Larson EL. Effect of hand hygiene on infectious disease risk in the community setting: a meta-analysis. *Am J Public Health* 2008;98:1372–81.
4. Burton M, Cobb E, Donachie P, Judah G, Curtis V, Schmidt WP. The effect of handwashing with water or soap on bacterial contamination of hands. *Int J Environ Res Public Health* 2011;8:97–104.

## QuickStats

FROM THE NATIONAL CENTER FOR HEALTH STATISTICS

### Percentage of Hospitalizations Ending in Death, by Selected First-Listed Diagnoses\* — National Hospital Discharge Survey, United States, 2000 and 2010



\* Data are for first-listed diagnosis coded according to the *International Classification of Diseases, 9th Revision, Clinical Modification* (ICD-9-CM) coding system. The codes for respiratory failure are 518.81, 518.83, and 518.84; septicemia 038; heart attack 410; cancer 140–209.36, 209.70–209.75, 209.79, and 230–234; and stroke 430–438. The percentage of hospital deaths was calculated by dividing the number of inpatients who died in the hospital within each category by the total number of inpatients in that category and then multiplying the resulting decimal by 100 to convert it to a percentage. Changes for the period 2000–2010 were tested using a trend test based on all data years.

† 95% confidence interval.

In both 2000 and 2010, 2% of all hospitalizations in the United States ended in death. The percentage of patients who died while hospitalized declined from 2000 to 2010 for inpatients with first-listed diagnoses of respiratory failure (25% compared with 17%), heart attack (10% compared with 8%), cancer (8% compared with 4%), and stroke (6% compared with 5%). By comparison, the percentage of inpatients hospitalized for septicemia who died in the hospital increased from 14% in 2000 to 16% in 2010.

Source: National Hospital Discharge Survey data, 2000–2010. Available at <http://www.cdc.gov/nchs/nhds.htm>.

Reported by: Shaleah Levant, MPH, [slevant@cdc.gov](mailto:slevant@cdc.gov), 301-458-4324; Marni Hall, PhD.



## Morbidity and Mortality Weekly Report

The *Morbidity and Mortality Weekly Report (MMWR)* Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format. To receive an electronic copy each week, visit *MMWR*'s free subscription page at <http://www.cdc.gov/mmwr/mmwrsubscribe.html>. Paper copy subscriptions are available through the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone 202-512-1800.

Data presented by the Notifiable Disease Data Team and 122 Cities Mortality Data Team in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. Address all inquiries about the *MMWR* Series, including material to be considered for publication, to Editor, *MMWR* Series, Mailstop E-90, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333 or to [mmwrq@cdc.gov](mailto:mmwrq@cdc.gov).

All material in the *MMWR* Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to *MMWR* readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of these sites. URL addresses listed in *MMWR* were current as of the date of publication.

U.S. Government Printing Office: 2012-523-043/02033 Region IV ISSN: 0149-2195